September 8, 2025

The Honorable Frank Pallone, Jr.
Ranking Member
Committee on Energy and Commerce
United States House of Representatives
Washington, DC 20515

The Honorable Ron Wyden
Ranking Member
Committee on Finance
United States Senate
Washington, DC 20515

The Honorable Robert C. "Bobby" Scott
Ranking Member
Committee on Education and Workforce
United States House of Representatives
Washington, DC 20515

The Honorable Richard Neal
Ranking Member
Committee on Ways and Means
United States House of Representatives
Washington, DC 20515

Dear Ranking Member Pallone, Ranking Member Wyden, Ranking Member Scott and Ranking Member Neal:

On behalf of the Alliance of Community Health Plans (ACHP), I'm sharing additional details on how our member companies are prioritizing access to immunizations that are safe, effective, and evidence-based. As outlined in our July 25 letter and reinforced in follow-up conversations with your staff, ACHP members remain committed to delivering high-quality preventive care and empowering patients to make the best decisions for themselves and their families.

We continue to actively engage with our member companies in light of evolving FDA approvals and CDC guidelines, as well as responses from professional organizations such as the American Academy of Pediatrics and the American College of Obstetrics and Gynecology. As a founding member of the Common Health Coalition—which brings together payers, providers and public health organizations to advance the nation's public health and health care delivery—we are also collaborating with industry partners and sharing vaccine-planning resources with our member companies.

Based on our engagement with member plan Chief Medical Officers and pharmacy leaders to date, ACHP member companies are not making changes to their COVID-19 vaccine coverage policies—including no cost sharing—for the 2025–2026 plan year. Plans will continue to work closely with their clinical care teams and Pharmacy and Therapeutics Committees to rigorously evaluate the

totality of vaccine safety and efficacy data and will align coverage decisions with the broader medical community and the best available scientific evidence.

We look forward to continuing to work with you, federal partners and the wider medical and public health community to support access to safe and affordable vaccines. For any additional information, please contact Dan Jones (djones@achp.org).

Sincerely,



Ceci Connolly
President and CEO
ACHP